A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Autorzy:
Gubin MM; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Zhang X; Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Schuster H; Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany. Caron E; Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland. Ward JP; 1] Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA [2] Department of Medicine, Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Noguchi T; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Ivanova Y; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Hundal J; The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA. Arthur CD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Krebber WJ; ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands. Mulder GE; ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands. Toebes M; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands. Vesely MD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Lam SS; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Korman AJ; Bristol-Myers Squibb, 700 Bay Road, Redwood City, California 94063, USA. Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA. Sharpe AH; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts 02115, USA. Pearce EL; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Schumacher TN; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands. Aebersold R; 1] Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland [2] Faculty of Science, University of Zurich, Zurich, 8093 Zurich, Switzerland. Rammensee HG; Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany. Melief CJ; 1] ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands [2] Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333ZA Leiden, The Netherlands. Mardis ER; 1] The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA [2] Department of Genetics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Gillanders WE; Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Artyomov MN; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA. Schreiber RD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Pokaż więcej
Źródło:
Nature [Nature] 2014 Nov 27; Vol. 515 (7528), pp. 577-81.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Autorzy:
Melero I; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain. Berman DM; Bristol-Myers Squibb, 3551 Lawrenceville Princeton, New Jersey 08648, USA. Aznar MA; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain. Korman AJ; Bristol-Myers Squibb Biologics Discovery California, 700 Bay Road, Redwood City, California 94063, USA. Pérez Gracia JL; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain. Haanen J; The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Autorzy:
Selby MJ; Bristol-Myers Squibb, Redwood City, CA, United States of America. Engelhardt JJ; Bristol-Myers Squibb, Redwood City, CA, United States of America. Johnston RJ; Bristol-Myers Squibb, Redwood City, CA, United States of America. Lu LS; Bristol-Myers Squibb, Redwood City, CA, United States of America. Han M; Bristol-Myers Squibb, Redwood City, CA, United States of America. Thudium K; Bristol-Myers Squibb, Redwood City, CA, United States of America. Yao D; Bristol-Myers Squibb, Redwood City, CA, United States of America. Quigley M; Bristol-Myers Squibb, Redwood City, CA, United States of America. Valle J; Bristol-Myers Squibb, Redwood City, CA, United States of America. Wang C; Bristol-Myers Squibb, Redwood City, CA, United States of America. Chen B; Bristol-Myers Squibb, Redwood City, CA, United States of America. Cardarelli PM; Bristol-Myers Squibb, Redwood City, CA, United States of America. Blanset D; Bristol-Myers Squibb, Redwood City, CA, United States of America. Korman AJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Sep 09; Vol. 11 (9), pp. e0161779. Date of Electronic Publication: 2016 Sep 09 (Print Publication: 2016).
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
Autorzy:
Colston E; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America. Grasela D; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America. Gardiner D; Infectious Diseases Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America. Bucy RP; Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America. Vakkalagadda B; Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Hopewell, New Jersey, United States of America. Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America. Lowy I; Translational Science and Clinical Oncology, Regeneron Pharmaceuticals, Tarrytown, New York, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Jun 07; Vol. 13 (6), pp. e0198158. Date of Electronic Publication: 2018 Jun 07 (Print Publication: 2018).
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
